Study of Lonidamine in Metastatic Breast Cancer
Author Information
Author(s): P. Pronzato, D. Amoroso, G. Bertelli, P.F. Conte, M.P. Cusimano, G.B. Ciottoli, M. Gulisan, R. Lionetti, R. Rosso
Primary Institution: Istituto Nazionale per la Ricerca sul Cancro
Hypothesis
The study aims to evaluate the activity and toxicity of lonidamine in patients with metastatic breast cancer.
Conclusion
Lonidamine shows some activity in previously treated metastatic breast cancer, with manageable toxicity.
Supporting Evidence
- Four partial responses were observed in 25 evaluable patients, representing a 16% response rate.
- Eleven patients experienced disease stability, accounting for 44% of the evaluable group.
- Toxicity was mainly myalgia (39%) and asthenia (21.4%), with no myelotoxicity observed.
- The median duration of response was 18 weeks.
- Patients were treated with lonidamine for a minimum of 8 weeks unless disease progression occurred.
Takeaway
This study tested a drug called lonidamine on women with advanced breast cancer, and it helped some of them feel better without causing serious side effects.
Methodology
Thirty patients with previously treated metastatic breast cancer were treated with oral lonidamine and evaluated for response and toxicity.
Limitations
The study had a small sample size and included only patients who were heavily pretreated.
Participant Demographics
Median age was 60 years, all participants were postmenopausal.
Statistical Information
Confidence Interval
95% confidence limits of 4-37% for partial responses.
Want to read the original?
Access the complete publication on the publisher's website